NCT00420238View on ClinicalTrials.gov

Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

May 31, 2009

Conditions

Ankylosing Spondylitis

Interventions

DRUG

Etanercept (Enbrel)

50 mg injection once weekly

OTHER

Placebo

placebo

Trial Locations (21)

1023

Budapest

4004

Debrecen

6202

Nice

12200

Berlin

13200

Arles

31000

Toulouse

33076

Bordeaux

34295

Montpellier

45032

Orléans

66330

Cabestany

67098

Strasbourg

75018

Paris (Bichat)

75571

Paris (Saint Antoine)

75651

Paris (Pitie Salpetriere)

75679

Paris (cochin)

80094

Amiens

84000

Avignon

91100

Corbeil-Essonnes

92401

Paris (Ambroise Pare)

446652

Herne

6229 HX

Maastricht

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00420238 - Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter